^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
revdofilimab (ABBV-368)
i
Other names: ABBV-368, ABBV368, ABBV 368, PR1628103
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
AbbVie
Drug class:
OX40 agonist
Related drugs:
3ms
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=150, Active, not recruiting, AbbVie | Trial completion date: Sep 2024 --> Mar 2025 | Trial primary completion date: Sep 2024 --> Mar 2025
Trial completion date • Trial primary completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
carboplatin • albumin-bound paclitaxel • budigalimab (ABBV-181) • giloralimab (ABBV-927) • revdofilimab (ABBV-368)
6ms
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=150, Active, not recruiting, AbbVie | Trial completion date: Nov 2023 --> Sep 2024 | Trial primary completion date: Nov 2023 --> Sep 2024
Trial completion date • Trial primary completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • PD-L1 negative
|
carboplatin • albumin-bound paclitaxel • budigalimab (ABBV-181) • giloralimab (ABBV-927) • revdofilimab (ABBV-368)
almost2years
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=150, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting
Enrollment closed • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • PD-L1 negative
|
carboplatin • albumin-bound paclitaxel • budigalimab (ABBV-181) • giloralimab (ABBV-927) • revdofilimab (ABBV-368)
2years
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=150, Recruiting, AbbVie | Trial completion date: Jul 2024 --> Nov 2023
Trial completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • PD-L1 negative
|
carboplatin • albumin-bound paclitaxel • budigalimab (ABBV-181) • giloralimab (ABBV-927) • revdofilimab (ABBV-368)
over2years
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=150, Recruiting, AbbVie | Trial completion date: Dec 2023 --> Jul 2024
Trial completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • PD-L1 negative
|
carboplatin • albumin-bound paclitaxel • budigalimab (ABBV-181) • giloralimab (ABBV-927) • revdofilimab (ABBV-368)
over2years
A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=139, Completed, AbbVie | Active, not recruiting --> Completed
Trial completion
|
PD-L1 (Programmed death ligand 1)
|
budigalimab (ABBV-181) • revdofilimab (ABBV-368)
almost3years
A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=170, Active, not recruiting, AbbVie | Trial completion date: Sep 2021 --> Feb 2022 | Trial primary completion date: Sep 2021 --> Feb 2022
Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1)
|
budigalimab (ABBV-181) • revdofilimab (ABBV-368)
almost4years
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=150, Recruiting, AbbVie | Trial primary completion date: May 2023 --> Nov 2023
Clinical • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • PD-L1 negative
|
carboplatin • albumin-bound paclitaxel • budigalimab (ABBV-181) • giloralimab (ABBV-927) • revdofilimab (ABBV-368)
4years
A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=140, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting | Trial completion date: Jan 2021 --> Sep 2021 | Trial primary completion date: Jan 2021 --> Sep 2021
Clinical • Enrollment closed • Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1)
|
budigalimab (ABBV-181) • revdofilimab (ABBV-368)
over4years
[VIRTUAL] A phase I study of CD40 agonist ABBV-927 plus OX40 agonist ABBV-368 with or without the PD-1 inhibitor budigalimab in patients with advanced solid tumors. (ASCO 2020)
Screening began on 21 May 2019, and enrollment is ongoing. Research Funding: Abbvie, Inc
Clinical • P1 data
|
TNFRSF4 (TNF Receptor Superfamily Member 4) • CD40 (CD40 Molecule)
|
budigalimab (ABBV-181) • giloralimab (ABBV-927) • revdofilimab (ABBV-368)
Share via
